In SpA and psoriasis, although the addition of MTX to anti-TNFs does not improve the efficacy of anti-TNFs (unlike RA), in the event of ADAb formation, concomitant use at the onset of anti-TNF therapy could provide another therapeutic option for clinicians to optimize treatment response and avoid the adverse consequences of immunogenicity. This evidence concerns the gene TNF and rheumatoid arthritis.